Avanos delivered a solid fourth quarter with net sales of $180.9 million and a significant improvement in operating income compared to the prior year's impairment-driven loss. While the company reported a small GAAP net loss, adjusted metrics showed resilience, particularly in the Specialty Nutrition segment which grew 8.7%. The company also provided 2026 guidance reflecting continued transformation and cost management efforts.

Avanos Medical, Inc. reported net sales of $167.5 million for the first quarter of 2025, an increase of 0.8% year-over-year. The company's net income was $6.6 million, and adjusted diluted earnings per share were $0.26. Operating income significantly improved to $10.3 million from $4.0 million in the prior year.